RCT and real-
As a protective wound covering, Affinity® was proven to support healing in a prospective, multicenter, randomized controlled trial (RCT)1
- Assessed efficacy of Affinity vs standard of care (SOC)* in 76 patients with refractory diabetic foot ulcers (DFUs) (>4 weeks' duration)
- Digital planimetry† accurately captured DFU area, depth, and volume
- Affinity significantly improved the incidence and time to wound closure (both P<0.05)
Significantly more DFUs were closed with Affinity than SOC at 8, 12 and 16 weeks (P=0.04)1
Frequency of wound closure‡
*Debridement, infection elimination, dressings, and offloading by total contact casting. †Silhouette® laser-assisted wound measurement device. ‡Estimated frequency of wound closure at weeks 8, 12 and 16; estimated from Cox adjusted survival data for wound closure.
Median time to DFU closure with Affinity was 11 weeks. SOC failed to attain this endpoint at 16 weeks.1
Significantly more DFUs achieved >60% reduction in wound area (P=0.02) and depth (P=0.04) and >75% reduction in volume (P=0.06) with Affinity than SOC1
*Debridement, infection elimination, dressings, and offloading by total contact casting. †Silhouette® laser-assisted wound measurement device.
Affinity, as a protective wound covering, has been shown to reduce wound area and support closure in a wide variety of wounds from head to toe.2-4
at 3 weeks
at 6 weeks
at 9 weeks
Affinity is intended to be used as a wound covering and barrier.
Please refer to the Affinity instructions for use for usage and safety information.
- Serena TE, et al. J Comp Eff Res. 2019. doi:10.2217/cer-2019-0142
- Lambert et al. Presented at: Symposium on Advanced Wound Care Fall 2015; September 26-28, 2015; Las Vegas, NV.
- Sabo M, et al. Chronic Wound Care Manage Res. 2018;5:1-4.
- Carpenter et al. Presented at: 4th Annual Innovations in Wound Healing Conference; December 7-10, 2017; Bimini, Bahamas.